{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117720","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.790346+00:00","generated_at":"2026-06-08T03:57:36.622935+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months","bullets":["Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.","Operating loss $18.5M (incl. $4.8M deSPAC costs); net loss $1.7M; diluted EPS loss $0.13.","PERIO-01 Phase 1 data: median PFS 11.7 months, DCR 81%, 1-year OS 86%.","PERIO-03 initial safety/feasibility for pancreatic cancer; dose expansion with anti-PD-1 expected early 2024.","Appointed Jodi Devlin as President, Commercial Operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117720","json":"https://secwatch.observer/filing/0001104659-23-117720.json","markdown":"https://secwatch.observer/filing/0001104659-23-117720.md","text":"https://secwatch.observer/filing/0001104659-23-117720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/0001104659-23-117720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/tm2330637d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:57:36.622935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54cb97ad4b4db11f2a1dbc3d2ebdbcc8dc46504f","claim":"TriSalus Life Sciences, Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $5.2 million, net income $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023, EPS Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0.","evidence_excerpt":"Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demonstrating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/0001104659-23-117720-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine month periods ended September 30, 2023"},{"label":"Revenue","value":"$5.2 million"},{"label":"Net income","value":"$1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023"},{"label":"EPS","value":"Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}